Y-mAbs Therapeutics Announced New Clinical And Preclinical Data From Studies Evaluating Naxitamab And GD2-SADA, Respectively, In Neuroblastoma
Y-mAbs Therapeutics Announced New Clinical And Preclinical Data From Studies Evaluating Naxitamab And GD2-SADA, Respectively, In Neuroblastoma
y-mabs therapeutics宣佈了評估Naxitamab和GD2-SADA在神經母細胞瘤中的新臨床和臨床前數據研究。
Y-mAbs Therapeutics Announced New Clinical And Preclinical Data From Studies Evaluating Naxitamab And GD2-SADA, Respectively, In Neuroblastoma
y-mabs therapeutics宣佈了評估Naxitamab和GD2-SADA在神經母細胞瘤中的新臨床和臨床前數據研究。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。